Altiratinib

中文名：Altiratinib

英文名：Altiratinib

纯度：Moligand™，≥99%

货号：A413439

Cas号：1345847-93-9

存储温度：-20°C储存

运输条件：超低温冰袋运输

产品介绍：

Information

Altiratinib (DCC-2701) is a potent single-digit nanomolar inhibitor ofTRK, Met (c-Met), TIE2, and VEGFR2 kinaseswith IC50 vaules of 0.9 nM, 4.6 nM, and 0.8 nM for TRKA, B, and C, respectively. It inhibits Met (c-Met) and Met (c-Met) mutant with IC50 values in the range of 0.3-6 nM.

Targets

MET Y1230C (Cell-free assay); TrkA (Cell-free assay); TrkC (Cell-free assay); MET Y1230C (Cell-free assay); MET D1228N (Cell-free assay) 31650,0.37 nM; 0.85 nM; 0.85 nM; 1.2 nM; 1.3 nM

In vitro

Altiratinib is >10-fold selective for MET versus FMS and KIT, and >50-fold selective for MET versus ABL1, FYN, HER1 (EGFR), p38α (MAPK14), PDGFRα, PDGFRβ, RET, and SRC. Altiratinib exhibits IC50s of 0.69 nmol/L in K562 cells, 1.2 nmol/L in SK-N-SH cells for inhibition of NGF-stimulated TRKA phosphorylation. Altiratinib inhibits constitutive TRKA phosphorylation with an IC50 of 1.4 nmol/L in KM-12 cells. Altiratinib inhibits HGF-stimulated MET phosphorylation in HUVECs, exhibiting an IC50 of 2.3 nmol/L. In ANG1-stimulated HUVECs and EA.hy926 cells, altiratinib exhibits IC50 values of 1.0 nmol/L and 2.6 nmol/L, respectively, for inhibition of TIE2 phosphorylation. In VEGF-stimulated HUVECs, altiratinib inhibits VEGFR2 phosphorylation with an IC50 of 4.7 nmol/L. Altiratinib potently inhibits cellular proliferation in MET-amplified EBC-1 and MKN-45 cells, as well as TPM3-TRKA fusion KM-12 cells, but only weakly inhibits other cancer cell lines, including proliferation of M-NFS-60 (IC50, 770 nmol/L); A375, BT-474, HCT-116, PC-3, SK-MEL-28, U87, and A549 cells (IC50s > 1,000 nmol/L).

Cell Research(from reference)

Cell lines：EBC-1, M-NFS-60, SK-MEL-28, MKN-45, MV-4-11, A375, HCT-116, BT-474, KM-12, PC-3, and U-87-MG cells

Incubation Time：72 h

查看阿拉丁官网此产品相关对应页面：http://www.aladdin-e.com/zh_cn/A413439.html